Jefferies Financial Group reissued their buy rating on shares of Haemonetics (NYSE:HAE) in a research report sent to investors on Tuesday, The Fly reports. They currently have a $125.00 target price on the medical instruments supplier’s stock. Jefferies Financial Group also issued estimates for Haemonetics’ Q2 2019 earnings at $0.54 EPS, Q3 2019 earnings at $0.59 EPS, Q4 2019 earnings at $0.56 EPS, FY2019 earnings at $2.28 EPS, FY2020 earnings at $3.30 EPS, FY2021 earnings at $4.25 EPS and FY2022 earnings at $4.95 EPS.

A number of other research firms also recently issued reports on HAE. Zacks Investment Research upgraded shares of Haemonetics from a hold rating to a buy rating and set a $105.00 target price for the company in a report on Tuesday, June 12th. TheStreet raised shares of Haemonetics from a c+ rating to a b rating in a research report on Tuesday, May 8th. Morgan Stanley lifted their price target on shares of Haemonetics from $77.00 to $100.00 and gave the company an overweight rating in a research report on Wednesday, May 9th. Barrington Research lifted their price target on shares of Haemonetics to $90.00 and gave the company an outperform rating in a research report on Wednesday, May 9th. Finally, ValuEngine raised shares of Haemonetics from a buy rating to a strong-buy rating in a research report on Monday, April 9th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and a consensus target price of $98.33.

Haemonetics traded down $0.22, reaching $99.74, during trading on Tuesday, Marketbeat reports. The company had a trading volume of 317,539 shares, compared to its average volume of 768,324. Haemonetics has a 12-month low of $41.10 and a 12-month high of $108.37. The company has a market cap of $5.26 billion, a price-to-earnings ratio of 53.34, a PEG ratio of 4.51 and a beta of 0.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.94 and a current ratio of 2.84.

Haemonetics (NYSE:HAE) last released its earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.17. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. The firm had revenue of $229.35 million during the quarter, compared to the consensus estimate of $219.52 million. sell-side analysts predict that Haemonetics will post 2.26 EPS for the current year.

In other Haemonetics news, VP Dan Goldstein sold 3,794 shares of Haemonetics stock in a transaction that occurred on Thursday, June 7th. The shares were sold at an average price of $95.09, for a total transaction of $360,771.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Michelle L. Basil sold 457 shares of Haemonetics stock in a transaction that occurred on Thursday, June 7th. The shares were sold at an average price of $92.73, for a total transaction of $42,377.61. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,711 shares of company stock worth $1,926,700. 1.04% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in HAE. Columbus Circle Investors lifted its position in shares of Haemonetics by 30.8% during the second quarter. Columbus Circle Investors now owns 260,678 shares of the medical instruments supplier’s stock worth $23,378,000 after purchasing an additional 61,375 shares in the last quarter. Swiss National Bank lifted its position in shares of Haemonetics by 2.2% during the first quarter. Swiss National Bank now owns 91,600 shares of the medical instruments supplier’s stock worth $6,701,000 after purchasing an additional 2,000 shares in the last quarter. OppenheimerFunds Inc. lifted its position in shares of Haemonetics by 1,584.7% during the first quarter. OppenheimerFunds Inc. now owns 197,852 shares of the medical instruments supplier’s stock worth $14,475,000 after purchasing an additional 186,108 shares in the last quarter. California Public Employees Retirement System lifted its position in shares of Haemonetics by 9.4% during the first quarter. California Public Employees Retirement System now owns 107,214 shares of the medical instruments supplier’s stock worth $7,844,000 after purchasing an additional 9,179 shares in the last quarter. Finally, Prudential Financial Inc. lifted its position in shares of Haemonetics by 65.4% during the first quarter. Prudential Financial Inc. now owns 246,715 shares of the medical instruments supplier’s stock worth $18,050,000 after purchasing an additional 97,559 shares in the last quarter. 99.58% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Article: Earnings Per Share

The Fly

Analyst Recommendations for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.